Abstract:CD4 mimics are small molecules that inhibit the interaction of gp120 with CD4. We have developed several CD4 mimics. Herein, hybrid molecules consisting of CD4 mimics with a long alkyl chain or a PEG unit attached through a self-cleavable linker were synthesized. In anti-HIV activity, modification with a PEG unit appeared to be more suitable than modification with a long alkyl chain. Thus, hybrid molecules of CD4 mimics, with PEG units attached through an uncleavable linker, were developed and showed high anti-HIV activity and low cytotoxicity. In investigation of pharmacokinetics in a rhesus macaque, a hybrid compound had a more effective PK profile than that of the parent compound, and intramuscular injection was a more useful administration route to maintain the high blood concentration of the CD4 mimic than intravenous injection. The presented hybrid molecules of CD4 mimics with a PEG unit would be practically useful when combined with a neutralizing antibody.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01153</a>.Experimental procedures of compound synthesis including characterization data, a calibration curve of YIR-821·2TFA used to calculate PK in a rhesus macaque, degradation experiments of the hybrid molecule 45 in the PBS solution (pH 7.4) at 37 °C, a calibration curve of the hybrid molecule 58·2TFA used to calculate PK in a rhesus macaque by iv injection, a calibration curve of 58·2TFA used to calculate PK in a rhesus macaque by im injection, the structures of YIR-821 and compound 58 docked in gp120, HPLC analysis of evaluation of the biological stability of compound 58·2TFA treated with human liver microsomes, FACS analysis of EGFP and HIV-1 JR-FL envelope (Env) expressing HEK293T cells treated with anti-CD4i antibodies, and inhibition of gp120-CD4 binding by compound 58 and YIR-821 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_001.pdf">PDF</a>)Molecular formula strings of 2–22, 24, 30, 32, 35, 36, 38–46, 49, 50, 54, 58, and 62 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Synthetic Peptides Derived from the Fourth Domain of CD4 Antagonize CD4 Function and Inhibit T Cell Activation

Bioactive Peptide Design Based on Protein Surface Epitopes: A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CC′ LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION

CD4 Function epitope and antagonist: their research advances

Design and synthesis of peptides as stabilizers of histone deacetylase 4

A5, a New Small-Molecule Inhibitor of CD4 D1 Obtained from a Computer-Aided Screening Method, Contributes to the Inhibition of CD4+ T-cell Function

Synthetic Peptides with Inadvertent Chemical Modifications Can Activate Potentially Autoreactive T Cells

A cyclic hexapeptide is a potent antagonist of alpha 4 integrins.

Inactivation of cell-free HIV-1 by designing potent peptides based on mutations in the CD4 binding site

Structure-Function Study and Anti-Hiv Activity of Synthetic Peptide Analogues Derived from Viral Chemokine Vmip-Ii

A synthetic bivalent ligand of CXCR4 inhibits HIV infection.

Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses

Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides.

Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-Trna Synthetase Interaction.

Potent inhibition of the CD4-dependent T cell response by J2, a novel nonpeptide organic ligand of CD4 D1.

Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

Rationally Designed Anti-HIV Peptides Containing Multifunctional Domains As Molecule Probes for Studying the Mechanisms of Action of the First and Second Generation HIV Fusion Inhibitors

Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120

Effect of a Cyclic Heptapeptide Based on the Human CD4 Domain 1 CC′ Loop Region on Murine Experimental Allergic Encephalomyelitis: Inhibition of Both Primary and Secondary Responses

Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors